Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.24.2.u1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
6 Months Ended
Jun. 30, 2024
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three-Month Periods Ended June 30, 

​

Six-Month Periods Ended June 30, 

($ in thousands)

    

2024

    

2023

    

2024

    

2023

Qbrexza®

​

$

6,836

​

$

8,079

​

$

11,853

​

$

12,173

Accutane®

​

 

5,719

​

 

5,579

​

 

11,538

​

 

10,227

Amzeeq®

​

​

1,205

​

​

1,374

​

​

1,960

​

​

2,568

Zilxi®

​

​

369

​

​

572

​

​

642

​

​

886

Other / legacy

​

​

726

​

​

1,357

​

​

1,892

​

​

3,272

Total product revenues

​

$

14,855

​

$

16,961

​

$

27,885

​

$

29,126

Schedule of other revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

    

Three-Month Periods Ended June 30,

    

Six-Month Periods Ended June 30,

($in thousands)

​

2024

    

2023

​

2024

    

2023

Other revenue

 

​

—

 

​

211

 

​

—

 

​

259

Total other revenue

​

$

—

​

$

211

​

$

—

​

$

259